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Metabolic reprogramming is emerging as a hallmark of the
innate immune response, and the dynamic control of metabo-
lites such as succinate serves to facilitate the execution of
inflammatory responses in macrophages and other immune
cells. Immunoresponsive gene 1 (Irg1) expression is induced by
inflammatory stimuli, and its enzyme product cis-aconitate de-
carboxylase catalyzes the production of itaconate from the tri-
carboxylic acid cycle. Here we identify an immunometabolic
regulatory pathway that links Irg1 and itaconate production to
the succinate accumulation that occurs in the context of innate
immune responses. Itaconate levels and Irg1 expression corre-
late strongly with succinate during LPS exposure in macro-
phages and non-immune cells. We demonstrate that itaconate
acts as an endogenous succinate dehydrogenase inhibitor to
cause succinate accumulation. Loss of itaconate production in
activated macrophages from Irg1/ mice decreases the accu-
mulation of succinate in response to LPS exposure. This meta-
bolic network links the innate immune response and tricarbox-
ylic acidmetabolism to function of the electron transport chain.
Immune cells must sense cues from the extracellular
microenvironment and respond rapidly to protect against bac-
teria, viruses, or other pathogens (1). An emerging hallmark of
inflammation and the innate immune system of cells is meta-
bolic reprogramming (2). One of the most general metabolic
changes that occurs under proinflammatory conditions is a bio-
chemical switch from oxidative phosphorylation to aerobic gly-
colysis (3–5), which is mediated, in part, via stabilization of
hypoxia-inducible factor 1 (HIF-1)2 after pathogen infection
(6), LPS binding to toll-like receptors (7), or by cytokine expo-
sure (8). Although it is known that macrophages undergo dras-
tic metabolic reprogramming upon exposure to inflammatory
stimuli, the underlying mechanisms driving this response are
not completely understood.
Increased succinate levels in macrophages are important
mediators of the inflammatory response, linkingmetabolism to
innate immunity. In addition to its role in TCA metabolism,
succinate acts as a regulatory signal enhancing Il-1 expression
through stabilization of HIF-1, which, in turn, influences the
function of various other metabolic pathways (9). Succinate
inhibits the hydroxylation of HIF-1 by EGLN1, resulting in
pseudohypoxic HIF-1 stabilization under normoxic condi-
tions (10–12). Various mechanisms have been proposed as the
cause of succinate accumulation, including increased gluta-
mine anaplerosis and oxidation in the TCA cycle or increased
flux through the GABA shunt (9, 13), although glycolytic
metabolism is a prerequisite (14). However, the specific driv-
er(s) of this phenomenon has/have not yet been identified.
Given the central role of succinate as a metabolic signal in
inflammation, elucidation of themetabolic pathway(s) involved
in succinate accumulation and its/their regulationmay provide
new avenues for controlling this process.
Metabolites are important functional triggers that can regu-
late the activity of enzymes via substrate/product inhibition,
posttranslational modifications, or allosteric interactions (15).
Beyond their direct roles as substrates and products, metabo-
lites often serve as substrates for posttranslational modifica-
tions, as shown for succinate to succinylate proteins (9). On the
other hand, fructose 1,6-bisphosphate (16), serine, and other
amino acids can allosterically influence the activity of the
enzyme pyruvate kinase isoformM2 (PKM2) (17, 18). Recently,
synthesis of the antimicrobial metabolite itaconate was identi-
fied in mammalian immune cells as being selectively up-regu-
lated under proinflammatory conditions (19). Itaconate exhib-
its an antibiotic function (20) via inhibition of isocitrate lyase, a
key enzyme of the glyoxylate shunt needed by many bacteria to
survive during infection (21–23). Inmammals, itaconate is pro-
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duced through the decarboxylation of the TCA cycle interme-
diate cis-aconitate, which is catalyzed bymammalian cis-aconi-
tate decarboxylase (CAD, also known as immune-responsive
gene 1 (IRG1) protein) encoded by immunoresponsive gene 1
(IRG1) (20). Itaconate production represents one of two char-
acteristic TCA cycle “break points” discovered in classically
activated immune cells (24, 25). The first break occurs at isoci-
trate dehydrogenase, leading to the accumulation of citrate, the
precursor for itaconate, and the second break occurs at succi-
nate dehydrogenase (SDH), which may allow for succinate
accumulation. Although itaconate has been shown previously
to inhibit SDH ex vivo (26–28), and LPS-activated murine
macrophages produced up to 8 mM intracellular itaconate (20),
a potential role of endogenously produced itaconate in succi-
nate accumulation under inflammatory conditions has not yet
been addressed and is unknown.
To elucidate the role of itaconate in reprogramming immune
cell metabolism, we modulated intracellular itaconate levels in
primary bone marrow-derived macrophages (BMDMs), a
macrophage cell line, as well as a lung adenocarcinoma cell line.
In all cellmodelswe observedmetabolic changes reminiscent of
SDH inhibition, including succinate accumulation. By measur-
ing substrate-specific mitochondrial respiration, we demon-
strated the inhibition of SDH by itaconate in a dose-dependent
manner. Furthermore, stimulated BMDMs from Irg1 KOmice
failed to produce itaconate and exhibited decreased succinate
accumulation compared with BMDMs from WT mice. Based
on these studies, we have elucidated an Irg1-induced immuno-
modulatory pathway inmacrophages whereby its product, itac-
onate, acts as an endogenously producedmetabolic regulator of
mitochondrial metabolism.
Experimental Procedures
Cell Culture and Isotopic Labeling—RAW 264.7 macro-
phages (29) (ATCC, TIB-71) and A549 cells (30) (ATCC, CCL-
185) were maintained in high-glucose DMEM (Life Technolo-
gies) supplemented with 10% (v/v) FBS, 100 unitsml1
penicillin/streptomycin, 25mM glucose, and 4mM L-glutamine.
Cell lines tested negative for mycoplasma contamination
using the MycoAlert mycoplasma detection kit (Lonza)
according to the instructions of the manufacturer. Purified
Escherichia coli LPS was used for the activation of RAW
264.7 macrophages and BMDMs at a concentration of 10
ngml1. A549 and RAW 264.7 cells and BMDMs were
exposed to increasing itaconate concentrations (5, 10, and 25
mM) for 6 h. For isotopic labeling experiments, RAW 264.7
macrophages were cultured in DMEM (Sigma) supple-
mented with 25 mM glucose, 4 mM [1-13C]glutamine (Cam-
bridge Isotopes Inc.) and 10% (v/v) dialyzed FBS for 24 h
prior to addition of LPS for 6 h. For isotope tracing with
exposure to unlabeled itaconate, RAW 264.7 cells were
exposed to labeled [U-13C6]glucose and [U-13C5]glutamine
tracers over a period of three subcultures and then exposed
further for 6 and 24 h to 10 mM unlabeled itaconate.
BMDMs—BMDM collection was approved by the Institu-
tional Animal Care and Use Committee and was conducted
according to the Guide for the Care and Use of Laboratory
Animals (US National Research Council, 2010). BMDMs were
isolated from femora and tibiae of C57BL/6J mice (The Jackson
Laboratory, Bar Harbor, ME). Bones were collected in ice-cold
PBS, cleaned of muscle, and flushed with 5 ml BMDM growth
medium (DMEM, Life Technologies) supplemented with 10%
(v/v) FBS, 100 unitsml1 penicillin/streptomycin, 25 mM glu-
cose, 4 mM L-glutamine, 20 ngml1 recombinant-macrophage
colony-stimulating factor (eBioscience), and 3.4 ll1 -mer-
captoethanol). Cells were seeded at 5 106 cells on Petri dishes
in 10 ml of growth medium. 5 ml of fresh growth medium was
added on day 3. On day 6, BMDMs were collected and replated
into 6-well tissue culture plates at a density of 5 105 cells/well
in growth medium containing 2 ngml1 recombinant-macro-
phage colony-stimulating factor.Metaboliteswere extracted on
day 7.
For Irg1 KO versusWTBMDM experiments, all animal pro-
cedures, such as handling and euthanasia, were performed
according to the Federation of European Laboratory Animal
Science Associations guidelines for the use of animals in
research. The Irg1 KO mice were generated by Dr. Haruhiko
Koseki at the RIKEN Institute using stem cells purchased from
the Knockout Mouse Project Repository under strain ID
Irg1tm1a(KOMP)Wtsi. Mice were anesthetized by intraperitoneal
injection of 50 mgkg1 of ketamine hydrochloride and 5
mgkg1 xylazine hydrochloride, and bonemarrowwas isolated
and cultured as described previously (31). Briefly, bonemarrow
was flushed from femora and tibiae of Irg1KOand age-matched
C57BL/6 WT mice, and the resultant cell suspension was
passed through a 70-m filter (Greiner Bio-One). After 10 min
of centrifuging at 250  g, the supernatant was discarded, and
the pellet was resuspended in 2 ml of hypotonic solution (170
mM NH4Cl) for 5 min to allow lysis of any remaining extracel-
lular red blood cells. Bone marrow-derived cells were plated in
12-well plates (Greiner Bio-One) at 5  105 cells/well. Cells
were cultured for 6 days at 37 °C in RPMI 1640 VLE (Very Low
Endotoxin) (Biochrom FG 1415) supplemented with 10% FBS
and 20% conditioned medium from macrophage colony-stim-
ulating factor-secreting L929 fibroblasts. After 6 days in cul-
ture, the BMDMs were used for experiments.
Metabolite Quantification—Metabolite levels of itaconate
and TCA cycle intermediates were quantified using external
standardcurves(threebiologicalreplicates).Formetabolitestan-
dard curves, increasing standard solutions were extracted
under the conditions of sample preparation. Using the depicted
standard curve, the metabolite quantity in each cell extract was
calculated, taking into account cellular diameter (d, microme-
ters) of detached cells and cell number.We assumed a spherical
shape and calculated the intracellularmetabolite concentration
using the following equation: [metabolite]metabolite quan-
tity (moles)/(((4/3000) (d/2)3) cell number). Cell number and
cell diameter were determined using a Countess automated cell
counter (Invitrogen).
Cell Transfections—Irg1 gain-of function experiments in
A549 cells were performed as described previously (20). Briefly,
A549 cells were transfected with the pCMV6-Irg1 (OriGene)
overexpressing plasmid or empty plasmid using Lipofectamine
2000 (Invitrogen) and further incubated for 24 h.
RNA Isolation and RT-PCR—Total RNA was purified from
cultured cells using the Qiagen RNeasy mini kit (Qiagen)
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according to the instructions of the manufacturer. First-strand
cDNA was synthesized from total RNA using SuperScript III
(Invitrogen) with 1 l (50 M)/reaction oligo(dT)20 as primer
according to the instructions of the manufacturer. Individual
20-l SYBR Green real-time PCR reactions consisted of 2 l of
diluted cDNA, 10 l of fast SYBR Green Master Mix (Applied
Biosystems), and 0.5 l of each 10 M forward and reverse
primers. For standardization of quantification, L27 was ampli-
fied simultaneously. PCRwas carried out in 96-well plates on an
Applied Biosystems ViiaTM 7 real-time PCR system using the
following program: 95 °C for 20 s, 40 cycles of 95 °C for 1 s, and
60 °C for 20 s (Irg1, GCAACATGATGCTCAAGTCTG (for-
ward) and TGCTCCTCCGAATGATACCA (reverse); L27,
ACATTGACGATGGCACCTC (forward) and GCTTGGCG-
ATCTTCTTCTTG (reverse)).
Oxygen Consumption Measurements—Respiration was mea-
sured in adherent monolayers of RAW 264.7 macrophages or
BMDMs using a Seahorse XF96 analyzer. RAW 264.7 macro-
phages were plated at 3  104 cells/well (for assays with per-
meabilized cells) and 4  104 cells/well (for assays with intact
cells) and BMDMs at 5  104 cells/well 24 h before measure-
ment. Intact cells were assayed inDMEM(Sigma, 5030) supple-
mented with 8 mM glucose, 3 mM glutamine, 3 mM pyruvate,
and 2 mM HEPES. Cells were permeabilized with 3 nM perfrin-
golysin O (commercially, XF PMP (XF PlasmaMembrane Per-
meabilizer)) as described previously (32). Phosphorylating
(state 3), succinate-driven respiration in permeabilized cells
was measured in cells offered 4 mM ADP, 2 M rotenone, two
different succinate concentrations (2.5 and 10 mM), and
increasing itaconate concentrations (0, 5, 10, and 25 mM).
When measuring respiration on different respiratory sub-
strates, permeabilized cells were offered succinate (10 mM)/ro-
tenone (2 M), glutamate/malate (each 10 mM), pyruvate/
malate (each 10 mM), or ascorbate (10 mM) plus N,N,N,N-
tetramethyl-p-phenylenediamine (TMPD) (100 M) and
antimycin A (1 M). Maximal respiration was calculated as the
difference between protonophore-stimulated respiration (600
nM carbonyl cyanide p-trifluoromethoxyphenylhydrazone) and
nonmitochondrial respiration (measured after addition of 1M
antimycin A). All data are mean S.E. of two or three repeated
experiments (with a minimum of five biological replicates per
experiment) as indicated in the text. For assays with BMDMs,
cells were obtained from three different mice.
GC-MS Sample Preparation and Analysis—Polar metabo-
lites were extracted using methanol/water/chloroform as
described previously (20). For medium metabolites, medium
was centrifuged at 4 °C for 5 min at 300 g. 10 l of superna-
tant was added to 80 l of a 20 °C 8:1 methanol/water mix-
ture, mixed for 10min at 4 °C, and centrifuged at 16,000 g for
10 min at 4 °C. 80 l was collected and evaporated under a
vacuum at 4 °C. Metabolite derivatization was performed
using a Gerstel MPS. Dried polar metabolites were dissolved in
15 l of 2% (w/v) methoxyamine hydrochloride (Thermo Sci-
entific) in pyridine and incubated for 60 min at 45 °C. An equal
volume of 2,2,2-trifluoro-N-methyl-N-trimethylsilyl-acet-
amide (MSTFA) or N-tert-butyldimethylsilyl-N-methyltrifluo-
roacetamide (MTBSTFA) with 1% tert-butyl dimethylchlorosi-
lane (Regis Technologies) was added and incubated further for
30 min at 45 °C. After derivatization, MSTFA-derivatized sam-
ples were analyzed as described previously (20). Briefly,
derivatized samples were analyzed by GC-MS using a
DB-35MS column (30 0.25 mm inner diameter 0.25 m,
Agilent J&W Scientific) installed in an Agilent 7890A gas
chromatograph interfaced with an Agilent 5975Cmass spec-
trometer. For MTBSTFA-derivatized samples, the GC oven
was held at 100 °C for 1 min, increased to 255 °C at 3.5 °C
min1, increased to 320 °C at 15 °C min1, and held at
320 °C for 3 min. The total run time for one sample was 54.62
min. For Irg1 KO versus WT BMDM metabolite measure-
ments, the GC oven was held at 100 °C for 2min, increased to
300 °C at 10 °C min1, and held at 325 °C for 3 min. The total
run time for one sample was 26 min.
MSTFA-derivatized metabolites were determined using the
following quantification ions: itaconate (m/z 259) and succinate
(m/z 247). Metabolite levels and mass isotopomer distribu-
tions of MTBSTFA-derivatized samples were analyzed by
integrating metabolite fragment ions (itaconate, m/z 301–
310; succinate, m/z 289–294; citrate, m/z 459–469; -keto-
glutarate, m/z 346–355; malate, m/z 419–428; and fumar-
ate, m/z 287–292) and corrected for natural abundance
using in-house algorithms.
Statistical Analysis—All results shown as averages of one to
three repeated experiments with each at least two biological
replicates as indicated in the text. A repeated experiment is
defined as a separate experiment temporally. Biological repli-
cates are defined as separate spatial replicates (i.e. wells of a
tissue culture plate) within an experiment. In the case of
BMDMs, repeated experiments are defined as cells from differ-
ent mice. Error bars indicate mean S.E. The statistical tool R
(33) was used to calculate the Pearson correlation coefficient.
For comparison of means between two different treatments,
the statistical analysis was done by two-tailed Student’s t test. *,
p 0.05; **, p 0.01; ***, p 0.001.
Results
Succinate and Itaconate Accumulate in LPS-activated RAW
264.7 Macrophages—To better understand the relationship
between Irg1-mediated itaconate production and the repro-
gramming of TCA metabolism under LPS-stimulated condi-
tions, we quantified the dynamics of itaconate and TCA inter-
mediate abundances in RAW264.7macrophages over time. To
elicit an immune response, we exposed RAW 264.7 macro-
phages to 10 ngml1 LPS for 6 h, conditions that induce high
expression of Irg1 encoding CAD, the enzyme catalyzing itac-
onate production from cis-aconitate (20). Intriguingly, the lev-
els of itaconate and succinate exhibited similar trends upon
activation, in contrast to the dynamics of citrate, -ketogl-
utarate, fumarate, and malate (Fig. 1a), suggesting that itacon-
ate and succinate (or the enzymes metabolizing them) are reg-
ulated in a coordinated manner. Notably, basal oxygen
consumption rates (OCR) remained unchanged comparedwith
resting macrophages (Fig. 1b).
Exogenous Itaconate Drives Succinate Accumulation—To
determine whether itaconate directly contributes to succinate
accumulation, we next supplemented the growth medium of
resting and LPS-activated murine RAW 264.7 macrophages
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with increasing itaconate concentrations for 6 h and observed
how intracellular itaconate levels correlated with those of
various TCA cycle intermediates (Figs. 2, a–f). LPS-activated
murinemacrophages can produce up to 8mM intracellular itac-
onate (20), but higher levels may accumulate in specific com-
partments (e.g. mitochondria). Therefore, we considered four
different itaconate concentrations ranging from 0–25 mM.
Exposure to exogenous itaconate resulted in increasing intra-
cellular itaconate levels in a dose-dependent manner (Fig. 2c),
indicating that cells have the capacity to take up itaconate from
medium.However,medium itaconate levels were not apprecia-
bly affected (Fig. 2g). Interestingly, no mitochondrial or plasma
membrane itaconate transporters have been described inmam-
malian cells to date.
We next calculated the Pearson correlation coefficient (r)
between the intracellular abundance of itaconate and eachTCA
intermediate to gauge the relationship across each pair. Intrigu-
ingly, we observed that intracellular itaconate levels correlated
strongly with succinate levels in resting (r  0.99) as well as
LPS-activated macrophages (r 0.99) so that higher itaconate
levels were associated with elevated succinate levels (Fig. 2e).
Importantly, the levels of other TCA intermediates, including
citrate,-ketoglutarate, fumarate, andmalate correlated poorly
(or in some cases negatively) with intracellular itaconate levels
(Fig. 2, a, b, d, and f). Because succinate accumulates after expo-
sure to exogenous itaconate in RAW 264.7 macrophages (Fig.
2e) as well as BMDMs (Fig. 2h), these data suggest that LPS-
induced itaconate production bymammalian CAD contributes
to the elevated succinate levels observed in activated macro-
phages. Importantly, exposure to exogenous itaconate induces
succinate accumulation in resting RAW 264.7 macrophages
(Fig. 2e) as well as resting BMDMs (Fig. 2h), indicating that the
mechanism through which itaconate acts is independent of
other inflammatory signaling events.
Itaconate and Irg1-induced Succinate Accumulation Is Not
Specific to Immune Cells—To further investigate whether itac-
onate reprograms TCAmetabolism independent of inflamma-
tory signals, we supplemented increasing itaconate concentra-
tions (0, 5, 10, and 25 mM) to the growth medium of human
A549 lung adenocarcinoma cells and quantified intracellular
metabolite concentrations after 6 h. As before (Fig. 2c), uptake
of extracellular itaconate from the medium was evidenced by
increasing intracellular itaconate levels (Fig. 3a), whereas
medium itaconate abundances did not change (Fig. 3b). Succi-
nate levels increased linearly with itaconate levels and corre-
lated strongly (r  0.99), whereas other TCA cycle intermedi-
ates, including citrate, -ketoglutarate, fumarate, and malate,
did not accumulate (Fig. 3a). These results are consistent with
our observations using RAW 264.7 macrophages (Fig. 2), and
because A549 cells do not express IRG1 (20) they suggest that
itaconate-mediated succinate accumulation occurs even in the
absence of an active inflammatory signaling cascade.
To determine whether CAD-mediated itaconate production
can affect succinate levels in non-immune cells, we overex-
pressed Irg1 in human A549 cells using a pCMV6-plasmid
encoding murine Irg1. Itaconate was only produced at detecta-
ble levels in pCMV6 Irg1-overexpressing A549 cells (pmIrg1)
compared with vector (pCMV6) controls (Fig. 3c). Notably,
pmIrg1 cells accumulated significantly higher amounts of suc-
cinate compared with pCMV6 controls (Fig. 3d), indicating
that ectopic expression of CAD alone is sufficient to impact
succinate levels. Collectively, these observations provide strong
evidence that itaconate functions as metabolic trigger to mod-
ulate succinate levels.
Itaconate Is Not Metabolized to Succinate—One explanation
for the above results could be that accumulated itaconate is
metabolized to succinate directly or indirectly in macrophages.
Indeed, Pseudomonas sp. can metabolize itaconate as a carbon
FIGURE 1. Succinate and itaconate accumulate in LPS-activatedmurine RAW 264. 7macrophages. a, dynamics of itaconate, succinate, citrate, -ketogl-
utarate, fumarate, andmalate levels. Cellswere exposed to 10 ngml1 LPS, andmetaboliteswere extracted every hour over a 6-h period. Graphs represent the
mean S.E. of time-dependent, intracellular metabolite concentrations [mM] of two repeated experiments, each with three biological replicates. b, the basal
OCR is unchanged in LPS-activated (LPS) macrophages compared with resting macrophages (Ctr). Error bars represent mean  S.E. of two repeated
experiments.
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source through cleavage into pyruvate and acetyl-CoA (34), and
a similar itaconate degradation pathway has been observed in
isolated liver mitochondria (35). To exclude the possibility that
degradation of itaconate to succinate occurs, we applied a
[1-13C]glutamine tracer to LPS-activated RAW 264.7 macro-
phages. During oxidative glutamine metabolism, decarboxyla-
tion of M1 -ketoglutarate derived from this tracer results in
M0 succinate. In contrast to the oxidative pathway, M1 -ke-
toglutarate is converted to M1 isocitrate and citrate via reduc-
tive carboxylation (36), subsequently leading to M1 itaconate
labeling. Thus, if itaconate is appreciably metabolized to succi-
nate through the aforementioned degradation pathways, then
we would detect significant labeling on succinate from this
tracer (Fig. 4a). Although we observed high fractions of M1
itaconate isotopologues (65%) because of itaconate produc-
tion via reductive glutamine metabolism, no labeling was
detected on succinate (Fig. 4b).
To further demonstrate that itaconate is not metabolized
to succinate, we cultured 13C-labeled resting and LPS-
activated RAW 264.7 macrophages in the presence of
10mM unlabeled itaconate and quantified succinate labeling.
We exposed cells to labeled [U-13C6]glucose and [U-13C5]
glutamine tracers over a period of three subcultures to
obtain adequate isotope enrichment in succinate pools (Fig.
4c). Because labeling of succinate after exposure to exoge-
nous, unlabeled itaconate was unchanged (even in the physi-
ological concentration used here) (Fig. 4d), these data therefore
confirm that itaconate is not metabolized to succinate in these
mammalian cells.
Itaconate Inhibits SDH—Although enhanced flux through
succinate-producing pathways from glutamine or glucose is
likely contributing to its accumulation in inflammatory cells,
our results suggest that itaconate degradation does not occur.
An alternative mechanism through which endogenous itacon-
ate could influence succinate levels is through inhibition of
SDH/complex II. Indeed, in vitro enzyme activity assays using
isolated SDH and respiratory studies have indicated that itac-
onate can reduce the activity of SDH (27, 28, 37). Mammalian
CAD is localized to mitochondria in murine macrophages (38);
therefore, itaconate production within or near this compart-
ment could modulate SDH activity and, subsequently, succi-
nate levels. To investigate the potential for itaconate to act as an
SDH inhibitor, we measured mitochondrial respiration in per-
meabilized murine RAW 264.7 macrophages and BMDMs.
First, we exposed permeabilized macrophages to increasing
itaconate concentrations (0–25 mM) in the presence of two
different succinate concentrations (2.5 and 10 mM) with 2 M
rotenone. Succinate is the substrate for complex II (SDH) of the
mitochondrial respiratory chain, whereas rotenone was used to
inhibit complex I and to prevent accumulation of the SDH
inhibitor oxaloacetate (39), enabling us to directly measure
maximal SDH-driven respiration. We observed a dose depen-
FIGURE 2. Exogenous itaconate drives succinate accumulation. Intracellular TCA cycle intermediate and itaconate quantification in resting (Ctr, continuous
line) and LPS-activated (LPS, dashed line) RAW 264.7macrophages after 6-h exposure to increasing extracellular itaconate concentrations (0, 5, 10, and 25mM)
(a, malate; b, citrate; c, itaconate; d, -ketoglutarate; e, succinate; f, fumarate). Cells were exposed to 10 ngml1 LPS for 6 h. Graphs represent themean S.E.
of intracellular metabolite concentrations [mM] of two repeated experiments, each with three biological replicates. Pearson correlation coefficient (r) repre-
sents correlation between intracellular itaconate and TCA cycle intermediate concentrations. g, medium itaconate levels of resting and LPS-activated RAW
264.7 macrophages (10 ngml1 LPS) at 0 h (black) and after 6 h (gray). Data represent themean S.E. of metabolite levels [mM] of three biological replicates.
h, intracellular succinatequantification in restingandLPS-activatedBMDMsafter 6-hexposure to0mM (black) or 25mM (gray) extracellular itaconate. Cellswere
exposed to 10 ngml1 LPS for 6 h. Graphs represent the mean  S.E. of succinate concentration [mM] obtained from two different mice, each with three
biological replicates. *, p 0.05; **, p 0.01.
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dent inhibition of OCRs by itaconate in RAW 264.7 macro-
phages (Fig. 5a) and BMDMs (Fig. 5b), suggesting a regulatory
role of itaconate for SDH activity. When the succinate concen-
tration was lowered to 2.5 mM, itaconate had a greater propor-
tional inhibitory effect. Considering the structural similarity of
succinate to itaconate (also known asmethylene succinate), our
data suggest that itaconate acts as a competitive SDH inhibitor
in immune cells, similar to the mechanisms described previ-
ously for the inhibition of purified SDH (27) and purified isoci-
trate lyase (22).
Next, to confirm that itaconate specifically inhibits SDH
rather than other mitochondrial pathways, we offered permea-
bilized RAW 264.7 macrophages various oxidizable substrates
and compared the maximal uncoupler-stimulated OCR in the
presence of 0 and 10 mM itaconate (Fig. 5c). As expected,
itaconate supplementation significantly reduced respiration
(	75%) in the presence of succinate (SDH substrate) and rote-
none (complex I inhibitor). On the other hand, oxygen con-
sumption rates in permeabilized cells in the presence of either
pyruvate with malate or glutamate with malate, substrates that
drive respiration via complex I activity, were not affected by
itaconate supplementation. Additionally, ascorbate and TMPD
were used to supply electrons for complex IV activity in the
presence of antimycin A, an inhibitor of complex III. Itaconate
also failed to impact this complex IV-mediated respiration.
Together, these data provide evidence that itaconate contrib-
utes to succinate accumulation in macrophages by acting as an
endogenous SDH inhibitor.
Loss of Irg1 Influences Succinate Levels in BMDMs—To
determine how succinate levels are affected in the absence of
endogenously produced itaconate, we analyzed BMDMs
derived from Irg1KOmice.We confirmed that Irg1mRNAwas
not expressed in LPS-stimulatedKO-derived BMDMs (Fig. 6a).
Consistent with this result, LPS-stimulated BMDMs from Irg1
KO mice failed to produce significant levels of itaconate (Fig.
6b). Notably, succinate concentrations in stimulated BMDMs
from Irg1 KOmice were significantly lower than those quanti-
fied in BMDMs from WT mice, suggesting that CAD-derived
itaconate influences succinate accumulation in LPS-induced
macrophages (Fig. 6c).
These results provide evidence that Irg1-mediated itaconate
production plays a role in succinate accumulation within
immune cells. Taken together, our data highlight amechanistic
function of itaconate whereby this metabolite acts as a SDH
FIGURE 3. Itaconate- and Irg1-induced succinate accumulation is not specific to immune cells. a, intracellular itaconate and succinate levels increase in
A549 lung adenocarcinoma cells after exposure to increasing exogenous itaconate concentrations (0, 5, 10, and 25 mM). Data represent the mean S.E. of
metabolite levels [mM] of two repeated experiments with each three biological replicates. b, itaconate levels in medium after 6 h (gray) are not significantly
affected compared with 0 h (black). Data represent the mean S.E. of metabolite levels of two repeated experiments with three biological replicates each. c
and d, intracellular levels of itaconate (c, black) and succinate (d, gray) increased in Irg1 overexpression A549 cells after transient transfection with murine
pCMV6-Irg1 overexpression (pmIrg1) plasmid compared with empty pCMV6-Entry (pCMV6) control plasmid. Error bars represent the intracellular metabolite
levels (ion counts) 24 h after transfection of three biological replicates (mean S.E.). *, p 0.05; **, p 0.01.
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inhibitor to influence TCA cycle metabolism by driving succi-
nate accumulation (Fig. 7).
Discussion
Here we have demonstrated an important function of itac-
onate; it acts as a key regulatory metabolite to modulate TCA
metabolismand succinate levels. In the cells studied, exogenous
and endogenous, CAD-produced itaconate strongly correlated
with succinate accumulation. Substrate-specific respirometry
studies in permeabilized cells confirmed that itaconate acts as
an SDH inhibitor. Finally, modulation of endogenous itaconate
production in LPS-activated primary macrophages from Irg1
KO mice reduces succinate levels. Thus, itaconate alters mito-
chondrial metabolism to influence succinate accumulation in
macrophages (Fig. 7).
Numerous metabolic pathways have been implicated in the
metabolic reprogramming of immune cells, in particular those
that regulate succinate levels, which, in turn, can influence HIF
signaling or other pathways (13, 25, 40, 41). Glutamine serves
as a major carbon source for succinate production in LPS-
activated macrophages via -ketoglutarate or, alternatively,
through the GABA shunt (9). A recent systems-based analysis
of macrophages under proinflammatory conditions described
key break points in TCA metabolism at isocitrate dehydroge-
FIGURE 4. Itaconate is not metabolized to succinate in RAW 264. 7 macrophages. a, carbon labeling indicating oxidative (black lines) and reductive (gray
lines) glutamine metabolism using [1-13C]glutamine. Labeled itaconate (M1) is only synthesized through reductive glutamine metabolism (gray), and if it is
metabolized to succinate, then it would result in succinate containing one labeled carbon (M1). b, mass isotopomer distribution of itaconate (black) and
succinate (white) of LPS-activated RAW 264.7 macrophages after 24-h exposure to [1-13C]glutamine tracer and 6-h exposure to 10 ngml1 LPS. The major
fraction of labeled itaconate contains one labeled carbon, whereas no labeling was found on succinate. Error bars represent the mean  S.E. of mass
isotopomer levels of three biological replicates. c, carbon labeling of TCA cycle intermediates using [U-13C6]glucose and [U-
13C5]glutamine tracers. If exoge-
nous, unlabeled itaconate ismetabolized to succinate, then labelingwould decrease but does not here. d, mass isotopomer distribution of succinate in resting
and LPS-activated RAW 264.7 macrophages after 6-h (black) and 24-h (gray) exposure to exogenous, unlabeled itaconate remains 90%, indicating that
itaconate is not metabolized to succinate. Cells were prelabeled with [U-13C6]glucose and [U-
13C5]glutamine over a period of three subcultures. Error bars
represent the mean S.E. of mass isotopomer levels of three biological replicates.
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FIGURE 5. Itaconate inhibits SDH. a and b, itaconate inhibits the OCR in (a) RAW 264. 7 macrophages and (b) BMDMs in a dose-dependent manner.
Shown are normalized OCRs of resting permeabilized cells exposed to increasing itaconate concentrations (0, 2.5, 5, 10, and 25 mM) with either 10 mM
(continuous line) or 2.5 mM (dashed line) succinate. Data represent the mean  S.E. of three repeated experiments. c, itaconate inhibits SDH of the
respiratory chain. Shown is the normalizedmaximal uncoupled OCR of permeabilized resting RAW 264.7 macrophages exposed to various substrates in
the presence of 0 mM (black) or 10 mM (white) itaconate. Data represent the mean S.E. of three repeated experiments normalized to conditions with
0 mM itaconate and 10 mM succinate.
FIGURE 6. Loss of Irg1decreases itaconate and succinate levels in Irg1KOBMDMs. a, Irg1 expression levels in LPS-activated (24 h, 10 ngml1 LPS) BMDMs
obtained from Irg1KOandWTmice. Error bars represent expression levels obtained from two independentmice (mean S.E.) relative to L27.b and c, itaconate
and succinate levels in BMDMs obtained from Irg1 KO and WT mice. Cells were activated for 6 h with 10 ngml1 LPS. Error bars represent mean  S.E. of
metabolite levels [mM] of six biological replicates obtained from two independent mice.
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nase and SDH (25). We have now identified a functional link
between these nodes of the TCA cycle, where itaconate pro-
duced by mammalian CAD at the first break-point regulates
SDH activity at the second break point.Within our analyses, we
did observe variability in succinate accumulation upon LPS
stimulation when comparing RAW 264.7 macrophages and
BMDMs. This variance is in the range of succinate accumula-
tion levels reported by others and is likely a function of cell,
medium formulation, and LPS variability (9). However, we con-
sistently observed increased succinate downstreamof itaconate
production or administration in a variety of cell types.
Succinate accumulation plays important roles during inflam-
mation so that it contributes to the induction of Il-1 expres-
sion via HIF-1 stabilization (9). Our results suggest that Irg1-
mediated itaconate production may influence downstream
inflammatory responses in macrophages (e.g. expression of
Il-1 or associated inflammatory genes). At present, it is not
known whether this inflammatory response is accomplished
directly by succinate or itaconate or mediated through other
mechanisms. Succinate inhibits HIF-1 signaling through inhi-
bition of PHD2 but can also impact the activity of numerous
-ketoglutarate-dependent dioxygenases (42, 43). As such,
itaconatemayhave pleiotropic effects on cells depending on the
expression,Ki, and compartment-specific impacts on succinate
concentrations. However, the physiological role of itaconate
and Irg1 require further investigations, particularly in the con-
text of macrophage development and differentiation. As noted
above, various other pathways (e.g. GABA shunt, glutaminoly-
sis) contribute to succinate synthesis inmacrophages and could
allow compensation (9, 13, 14). Intracellular signaling pathways
also play key roles inmacrophage polarization and likely sustain
inflammation to some degree in the absence of Irg1 (44).
Given the diverse effects of inflammation in human disease,
themechanistic interplay between itaconate and succinate is of
clinical interest. Itaconate was only recently identified as an
endogenous mammalian biochemical (19), and subsequent
studies demonstrated that this molecule was produced by
mammalian CAD activity on cis-aconitate (20). Itaconate
reprograms the metabolism of pathogens, such as Mycobacte-
rium tuberculosis, by inhibition of isocitrate lyase, a key enzyme
in the glyoxylate shunt (45); thus, macrophages produce the
antimicrobial metabolite itaconate to combat against invading
pathogens (20). Following these discoveries, it has recently been
speculated that itaconate might contribute to the function of
innate immune cells (2, 46). Importantly, IRG1 is induced by
various non-bacterial stimuli, including influenza A viral infec-
tion (47), Marek disease infection (48), during embryonic
implantation (49), neurotropic viral infections of neurons (50),
and in murine epidermal cells (51). Given the regulatory role of
itaconate in succinate accumulation described here, IRG1-me-
diated itaconate production may act as a signaling molecule in
other inflammatory situations or cellular states. Indeed, succi-
nate can inhibit various other -ketoglutarate-dependent
dioxygenases to impact diverse cellular processes (42, 43). On
the other hand, the mechanism outlined here for SDH inhibi-
tion could be used to mitigate pathogenic inflammation under
certain circumstances (e.g. via CAD inhibition). For example,
high levels of succinate have also been reported to occur under
ischemic conditions because of reverse SDH activity (40, 41).
The accumulated succinate is rapidly oxidized after reperfu-
FIGURE 7. Mechanism of LPS-induced succinate accumulation. Under inflammatory conditions, such as LPS stimulation, mammalian CAD catalyzes the
decarboxylation of the TCA cycle intermediate cis-aconitate to produce itaconate. This metabolite contributes to succinate accumulation in macrophages by
acting as an endogenous SDH inhibitor.
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sion, resulting in increased mitochondrial reactive oxygen spe-
cies production and damage. A similar mechanism has been
speculated to occur during sepsis (52). Notably, SDH inhibition
protected against brain injury after ischemia/reperfusion (40,
41), suggesting that inhibition of SDH by endogenously pro-
duced itaconate may buffer against potential oxidative damage
that can occur under such conditions.
Our findings provide critical new insights into the regulatory
machinery governing TCA cycle function, with mammalian
CAD-produced itaconate serving as a metabolic inhibitor to
cause succinate accumulation. Ultimately, these results may be
clinically important when drugs that target such metabolic
inflammatory signals are identified. The emerging role of itac-
onate as a regulatory molecule to reprogram immune cell
metabolism provides an intriguing link between innate immu-
nity, metabolism, and disease pathogenesis.
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